Abstract
The drug use-results survey, as well as the spontaneous reporting system, is an important measure to collect the post-marketing safety and effectiveness information of drugs;many drugs have already been evaluated.
The data collected through the drug use-results surveys is submitted to the authorities as part of the application documents for drug reevaluation, but has seldom been used for pharmacoepidemiological research despite its potential for such use.
We propose the authority to make full use of the drug use-results survey data for pharmacoepidemiological research by developing a database of the collected data after standardization of the survey items such as adverse events, and disease-specific background information of patients.
